Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-ioduced parkinsonism in monkeys

Since there are reasons to hypothetize that appropriate occupation of D 1 receptors may be an essential component of efficacious antiparkinsonian therapy (Brewster et al., 1990), we tested dihydrexidine in non-human primates pretreated with the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-HCl (MPTP), which results in a parkinsonian syndrome in humans and non-human primates